News
February 5, 2020
Jail-Based Intervention Increases Post-Release Initiation of Medication Treatment for OUD
People with opioid use disorder (OUD) are frequently incarcerated and, as a result, jails house many individuals with OUD. OUD goes largely untreated during periods of incarceration. Additionally, the risk of relapse to opioid use, as well as opioid-induced overdose, is very high after release from incarceration, with former inmates having an approximately 10-fold higher…
February 3, 2020
Seattle to Distribute Naloxone Kits & Hold Trainings to Counter Fentanyl Overdoses
The city of Seattle will be distributing 700 naloxone kits and convening 25 training sessions with community organizations as part of an effort to counter overdoses caused by fentanyl. ADAI staff Alison Newman and Caleb Banta-Green provided input on the mayor’s plan and will be delivering many of the naloxone trainings. For more about this…
January 7, 2020
Kudos to Dennis Donovan!
This review co-authored by ADAI’s former director Dr. Dennis Donovan has been read online 5000 times – Well done! Marlatt GA, Baer JS, Donovan DM, Kivlahan DR (1988). Addictive behaviors: etiology and treatment. Annual Review of Psychology 39:223-52. If you want to read this article, request a copy from adai@uw.edu
December 23, 2019
King County’s “Bupe Pathways” Program is a National Model
A widely-reprinted national news story featured King County’s local “Bupe Pathways” program, which provides client-centered care and rapid access to medications that treat opioid use disorder. The quick access model that offers effective medications is gaining national attention. But finding a prescriber without a waiting list is difficult. Guidelines say bupe should be used alongside…
December 11, 2019
Research Suggests Naloxone May Be Good Past Its Expiration Date
Naloxone products typically have an expiration date (“shelf life”) approximately 18-24 months from the date of manufacture. Expiration dates are based on how long a manufacturer guarantees the full potency and safety of a drug. Two peer reviewed articles have tested the stability of naloxone: A 2006 article examined the stability of an array of…
December 10, 2019
Bia Carlini Named Director, UW Tobacco Studies Program
Dr. Bia Carlini, PhD, MPH, has been named as the new director of the Tobacco Studies Program in the School of Public Health, beginning December 15, 2019. Her earlier participation in the TSP convinced her to focus her career on tobacco control: as part of the first cohort of tobacco scholars, (2003-4), her tobacco-related practicum…
December 2, 2019
UW Researchers Find Clue to Preventing Addiction Relapse
A study by ADAI Director Dr. Susan Ferguson was able to control relapse to heroin use in rats by using chemogenetic receptors to act as a “light switch” on neurons in the nucleus accumbens region of the brain. This process could prevent relapse for other addictions, like compulsive gambling or overeating, which affect the same…
November 25, 2019
Inside One of Seattle’s Biggest Opioid Busts
ADAI scientist Caleb Banta-Green was interviewed for a fascinating story about the drug fentanyl, and the multi-state effort to bring down a leading drug dealer in Seattle. Read the full story at Seattle Met . . .
November 14, 2019
Speaking from the Heart: The Parent-Child Assistance Program (PCAP)
The Parent-Child Assistance Program (PCAP) is an award-winning home visitation case‐management intervention working with a challenging population: pregnant and parenting women who have substance use disorders and trauma histories. Begun in 1991 at the University of Washington, PCAP now operates in fifteen counties throughout Washington State with the goals of helping mothers build healthy families…
Highly Potent Opioid Carfentanil Found in Seattle
Carfentanil, an opioid 10,000 times more potent than morphine and 100 times stronger than fentanyl, is showing up in Seattle with increasing frequency. In a KOMO News interview, ADAI principal scientist Caleb Banta-Green warns that users don’t know what they’re getting, or the dangers of this drug. View the full story on KOMO News. In…
Previous page Next page
